In the current analysis, 111 patients were previously treated with a PD-(L)1 inhibitor in the metastatic setting while only 22 had PD-L1 positive results; this may be the result of missingness in the database (70% of patients had an unknown PD-L1 expression status); alternatively, patients may have been positive for microsatellite instability-high and tumor mutational burden-high as pembrolizumab is a preferred treatment for these patients [12]. Here, CD274 is linked to neoplasm.